Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703339 · ClinicalTrials.gov registry record · Phase 2
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Lung Biotechnology PBC.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00703339 is a Phase 2 study that was terminated before completion, run by Lung Biotechnology PBC. The registered enrollment target is 1 participants.
The verdict
NCT00703339, a Phase 2 study, was terminated before completion, sponsored by Lung Biotechnology PBC.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a range of tolerable doses. The safety and pharmacodynamic information obtained from this study will inform the design and conduct of future studies in inhaled treprostinil sodium in this population.
Interventions
- DRUG Treprostinil sodium for inhalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00703339
The ClinicalTrials.gov registry entry for NCT00703339 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lung Biotechnology PBC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treprostinil sodium for inhalation is the first listed.
NCT00703339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00703339 about?
NCT00703339 is a clinical study titled "Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis". The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a range of tolerable doses. The safety and pharmacodynamic information obta...
What is the current status of trial NCT00703339?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00703339?
The interventions under investigation include: Treprostinil sodium for inhalation (DRUG).
Who is sponsoring clinical trial NCT00703339?
This trial is sponsored by Lung Biotechnology PBC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.